

CASE STUDY

Cleveland Clinic Aims to Improve Multiple Sclerosis Diagnosis By Studying New Central Vein Sign Biomarker

Cleveland Clinic

Overview

The need for improved diagnostic methods in MS is widely recognized. Although MRI is a longstanding tool for detecting MS lesions, diagnostic inaccuracies persist.

Up to 20% of people diagnosed with MS are later found not to have the disease. The Central Vein Sign was identified as a potential new biomarker to differentiate MS from other white matter lesions.

The Challenge

Providing expert neuroscientific support, data storage, transfer, management, protocol and QA analysis of imaging and clinical data in the format of eCRFs, during the course of the project. Implementing AI algorithm analysis of the medical images using a customized workflow.

Results

The QMENTA Platform managed data for 500 patients from 10 sites over 2 years, including executing custom advanced imaging analysis and 23 custom eCRF forms. This successful study resulting in the joint publication of a scientific paper on a new MS biomarker.

Q www.qmenta.com

-Daniel Ontaneda, MD, PhD, Co-principal Investigator, Cleveland Clinic Mellen Center for Multiple Sclerosis

Scientific support, study management and quantitative data analysis using **QMENTA**'s cloud-based workflow for evaluating the Central Vein Sign for MS diagnosis.

